Notizie dei mercati

Entrada Therapeutics, Inc.: Goldman Sachs mantiene la raccomandazione Neutral

This content has been archived. It may no longer be relevant

Entrada Therapeutics, Inc.: Goldman Sachs mantiene la raccomandazione Neutral

Entrada Therapeutics Goldman


FIMA2681# 2022-08-15T17:01:13+02:00

Show More